Negative Consequences of Removing GLP‐1 RA Obesity Coverage: A Cross‐Sectional Cohort Comparison Study
Obesity Science & Practice · 2026-04 · 12 (2)
DOI: 10.1002/osp4.70123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Obesity Science & Practice, online erschienen am 03.03.2026. Verfasst von Jackson M Francis und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Peter O'Donnell School of Public Health, University of Texas Southwestern Medical Center Dallas Texas USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS.
Abstract (Originalsprache)
Objective
GLP‐1 receptor agonist (GLP‐1 RA) coverage decisions for obesity have major health and economic implications. This study examined how loss of GLP‐1 coverage affected employee perceptions of their employer and workforce stability.
Methods
This study analyzed data from employees of a healthcare system that discontinued GLP‐1 obesity medication coverage. Outcomes were evaluated using chi‐square/Fisher's exact tests and multivariable logistic regression.
Results
Two hundred forty‐seven adults prescribed GLP‐1 for obesity who lost coverage (mean age 49.27 years—SD: 9.89, BMI 32.85 kg/m 2 —SD: 8.49); 90.28% were female, 40.08% non‐Hispanic White, 30.36% non‐Hispanic Black, 19.84% Hispanic, and 9.72% Other. Following loss, 80.57% reported worsened employer perceptions, 17.81% considered changing jobs, 49.39% felt devalued, and 64.38% believed their employer didn't value their health. Burnout was common (88.67% past year; 65.19% past month). NHB and Hispanic employees were less likely than NHW to report worsened employer relationships (aOR = 0.29 and 0.34), while those with incomes ≥ $150,000 were 2.5x as likely to report negative impact (aOR = 2.57).
Conclusion
Loss of GLP‐1 coverage was linked to reduced employee satisfaction, increased burnout, and greater turnover risk. Lower reported impact among NHB and Hispanic employees may reflect disparities in perceived job mobility. These consequences may undermine workforce stability and offset cost savings that motivate coverage restrictions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Epidemiology, Peter O'Donnell School of Public Health, University of Texas Southwestern Medical Center Dallas Texas USA.
- Department of Epidemiology, School of Public Health, University of Texas Health Science Center at Houston Houston Texas USA.
- Department of Internal Medicine Division of Endocrinology University of Texas Southwestern Medical Center Dallas Texas USA.
- Department of Epidemiology, School of Public Health, University of Texas Health Science Center at Houston Dallas Texas USA.
- Department of Pediatrics University of Texas Southwestern Medical Center Dallas Texas USA.
- Children's Health System of Texas Dallas Texas USA.
ORCID-Profile: Jackson M Francis, Deepali K Ernest, Marianne Olaniran
Förderung
- NIDDK NIH HHS
Zitieren
APA
Francis, J. M., Ernest, D. K., Chandrasekhar, A., Herrington, G., Gazda, C., Xie, L., Mathew, M. S., Olaniran, M., Messiah, S. E., & Almandoz, J. P. (2026). Negative Consequences of Removing GLP‐1 RA Obesity Coverage: A Cross‐Sectional Cohort Comparison Study. Obesity Science & Practice, 12(2). https://doi.org/10.1002/osp4.70123
Vancouver
Francis JM, Ernest DK, Chandrasekhar A, Herrington G, Gazda C, Xie L, et al. Negative Consequences of Removing GLP‐1 RA Obesity Coverage: A Cross‐Sectional Cohort Comparison Study. Obesity Science & Practice. 2026;12(2). doi:10.1002/osp4.70123
BibTeX
@article{Francis2026,
author = {Francis, Jackson M and Ernest, Deepali K and Chandrasekhar, Aparajita and Herrington, Grant and Gazda, Chellse and Xie, Luyu and Mathew, M Sunil and Olaniran, Marianne and Messiah, Sarah E and Almandoz, Jaime P},
title = {Negative Consequences of Removing GLP‐1 RA Obesity Coverage: A Cross‐Sectional Cohort Comparison Study},
journal = {Obesity Science & Practice},
year = {2026},
volume = {12},
number = {2},
doi = {10.1002/osp4.70123}
}
EUVIMED